
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …

Psoriasis is a big pharmaceutical market, it’s the most common autoimmune disease in the US and as many as 7.5 …

New data has revealed that the number of UK patients seeking talking therapies on the NHS is on the rise, …

AbbVie revealed that its IL-23 inhibitor, risankizumab, had successfully met all of its endpoints in a Phase 3 trials into …

We are proud to be partnering with the ProcureCon Pharma 2018, the only event in Europe for senior pharma procurement …

Akili, an unlisted affiliate of London-listed PureTech Health, has unveiled top-line results of AKL-T01, a novel digital medicine which takes …

Derek Wallace, Global Dengue Program Head at Takeda Vaccine Business Unit, discusses the recent Phase 2 results showing its vaccine …

The conflict and poor economic situation in Yemen is creating a “perfect mix” for a resurgence of cholera in the …

The Philippines has announced that it will investigate how more than 730,000 children received a dengue vaccine, despite safety concerns …

The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …

As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the …

It’s no secret that when individuals leave companies within the pharma industry, they tend to pop up at a rival …

Scott Gottlieb, FDA commissioner, was speaking in front of the House Committee on Energy and Commerce, regarding the 21st Century …

Image Credit: Marco VerchAs the US languishes in the midst of an opioid crisis which President Trump declared national emergency …

New research published in The Lancet has revealed that type 1 diabetes cannot be understood as a “disease of the …